Showing 6941-6950 of 8837 results for "".
- ABMS Announces Class of 2023-2024 Visiting Scholarshttps://practicaldermatology.com/news/abms-announces-class-of-2023-2024-visiting-scholars/2461993/Gillian Heinecke, MD, an assistant clinical professor at SSM Health/Saint Louis University in St. Louis, Mo. is the American Board of Dermatology’s 2023-2024 Visiting Scholar. The American Board of Medical Specialties (ABMS) selected thirteen outstanding indivi
- The Complexion of Climate in Medical Educationhttps://practicaldermatology.com/news/the-complexion-of-climate-in-medical-education/2461992/The morning news warned us of a heatwave, but that didn’t stop 8-year-old me from putting on my usual red hoodie. The avoidance of prying eyes or hearing “is it contagious?” another time made the sweating worth it. Atopic dermatitis (AD) had claimed my skin as its home, marking
- DermTech Appoints Mark Aguillard as Chief Commercial Officerhttps://practicaldermatology.com/news/dermtech-appoints-mark-aguillard-as-chief-commercial-officer/2461990/Mark Aguillard is DermTech, Inc.’s chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. Prior to joining is DermTech, Mr. Aguillard served as the chief commercial officer of Epic
- Meet Secret DUO from Cuterahttps://practicaldermatology.com/news/meet-secret-duo-from-cetera/2461986/Cutera, Inc. is launching Secret DUO, a skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies. Each modality can be used individually or in combination to target a wide range of aesthetic indications. Secret DUO is equipped
- Tarsus Rolls Out XDEMVY for Demodex Blepharitishttps://practicaldermatology.com/news/tarsus-rolls-out-xdemvy-for-demodex-blepharitis/2461985/Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis. XDEMVY is now available at pharmacies nationwide for prescription. Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, ran
- Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co. Ltd. for Qbrexza in South Korea, Other Asian Nationshttps://practicaldermatology.com/news/journey-medical-corporation-enters-into-an-exclusive-license-agreement-with-maruho-co-ltd-for-qbrexza-in-south-korea-other-asian-nations/2461983/Journey Medical Corporation has entered into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations. Maruho Co., Ltd. is Journey’s exclusive licensing partner that developed and is commercializing Qbrexza (Rapifort) in Japan.&n
- CDC Warns Doctors to Lookout for Flesh-eating Bacteria in Woundshttps://practicaldermatology.com/news/cdc-warns-doctors-to-lookout-for-flesh-eating-bacteria-in-wounds/2461981/Healthcare providers, laboratories, and public health departments need to be on the lookout for Vibrio vulnificus (V. vulnificus) infections in wounds that were exposed to coastal waters, particularly near the Gulf of Mexico or East Coast, and during periods with
- Spotlight on Snail Mucushttps://practicaldermatology.com/news/spotlight-on-snail-mucus/2461980/Snail mucus is widely used in cosmetics, moisturizers, anti-aging creams, wound care treatments, and antimicrobials, but what is it, really? This was the question posed by researchers in a new study that examines the molecular composition of snail mucus. When analyzing the mucus of a co
- Melanoma Discovery: Understanding the Role of GREB1 Isoform4 in Melanomahttps://practicaldermatology.com/news/melanoma-discovery-understanding-the-role-of-greb1-isoform4-in-melanoma/2461979/GREB1 Isoform4 (Is4) is involved in pyrimidine synthesis and causes malignant melanoma, suggesting GREB1 Is4 a new therapeutic target for melanoma, according to a study in Oncogene. The expression of a specif
- Dan Walker Named VP of US Commercial Operations at SciBasehttps://practicaldermatology.com/news/dan-walker-named-vp-of-us-commercial-operations-at-scibase/2461977/Dan Walker is SciBase’s new VP of US Commercial Operations. SciBase's products include Nevisense and Nevisense Go which address melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. Mr. Walker was previously Senior Dire